Document:

Exhibit
10.1

WHEREAS,
Regen Biopharma, Inc. (the “Company”) wishes to reward and compensate David Koos (“Employee) for Employee’s
efforts in addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to the
Company’s Investigational New Drug Application for HemaXellerate.

WHEREAS,
Employee’s efforts have resulted in securing the consent of the FDA allowing the Company to initiate a Phase I clinical
trial assessing HemaXellerate in patients with drug-refractory aplastic anemia

WHEREAS,
the Company benefits greatly for having been granted the consent of the FDA allowing the Company to initiate a Phase I clinical
trial assessing HemaXellerate in patients with drug-refractory aplastic anemia

THERFORE,
IT IS AGREED AS FOLLOWS:

		1.	As
                                         bonus consideration for Employee’s labors, The Company shall award to Employee
                                         10 million shares of the Company’s Series A Preferred Stock, par value $0.0001(“Compensation
                                         Shares”)

		2.	Employee
                                         acknowledges that Compensation Shares have not been registered under the Securities Act
                                         of 1933, as amended (the “Act”), or securities laws of any state and may
                                         not be offered, sold, assigned, pledged, transferred or otherwise disposed of in the
                                         absence of an effective registration statement under the Act and applicable state securities
                                         laws or pursuant to an available exemption from registration under the Act or such laws.

		3.	Company
                                         hereby represents and warrants to Employee as follows;

 

		(i)	Corporate
                                         Existence of Company.

Company:

 

(a)
is a corporation duly formed, validly existing and in good standing under the laws of the State of Nevada and

 

(b)
has all requisite power and authority, and has all governmental licenses, authorizations, consents and approvals necessary to
execute and deliver this Agreement and to consummate the transactions contemplated by this Agreement.

 

(ii)
No Conflicts. None of the execution, delivery and performance of this Agreement by Company, or the consummation or the transactions
contemplated hereby and thereby

 

 

(a)
constitutes or will constitute a violation of the organizational documents of Company,

 

(b)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice or lapse of time or both,
would constitute such a default) under, any indenture, mortgage, deed of Company, loan agreement, lease or other agreement or
instrument to which Company is a party or by which Company or any of its properties may be bound, 

 

(c)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court or Governmental
Authority directed to Company or any of its properties in a proceeding to which its property is or was a party.

 

		4.	The
                                         terms and conditions of this Agreement shall be governed by and construed in accordance
                                         with the laws of the State or California. Any action to enforce this Agreement shall
                                         be brought in the state courts located in San Diego County, State of California.

 

Signed
in agreement

 

	/s/ David Koos	 	 
	David Koos, Chairman & CEO	 	 
	“Company”	 	 
	Dated: April 6, 2016	 	 
	 	 	 

 

Signed
in acceptance

 

	/s/ David Koos	 	 
	“Employee”	 	 
	Dated: April 6, 2016Exhibit
10.2

WHEREAS,
Regen Biopharma, Inc. (the “Company”) wishes to reward and compensate Harry Lander PhD (“Employee) for Employee’s
efforts in addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to the
Company’s Investigational New Drug Application for HemaXellerate.

WHEREAS,
Employee’s efforts have resulted in securing the consent of the FDA allowing the Company to initiate a Phase I clinical
trial assessing HemaXellerate in patients with drug-refractory aplastic anemia

WHEREAS,
the Company benefits greatly for having been granted the consent of the FDA allowing the Company to initiate a Phase I clinical
trial assessing HemaXellerate in patients with drug-refractory aplastic anemia

THERFORE,
IT IS AGREED AS FOLLOWS:

		5.	As
                                         bonus consideration for Employee’s labors, The Company shall award to Employee
                                         10 million shares of the Company’s Series A Preferred Stock, par value $0.0001(“Compensation
                                         Shares”)

		6.	Employee
                                         acknowledges that Compensation Shares have not been registered under the Securities Act
                                         of 1933, as amended (the “Act”), or securities laws of any state and may
                                         not be offered, sold, assigned, pledged, transferred or otherwise disposed of in the
                                         absence of an effective registration statement under the Act and applicable state securities
                                         laws or pursuant to an available exemption from registration under the Act or such laws.

		7.	Company
                                         hereby represents and warrants to Employee as follows;

		(ii)	Corporate
                                         Existence of Company.

Company:

 

(a)
is a corporation duly formed, validly existing and in good standing under the laws of the State of Nevada and

 

(b)
has all requisite power and authority, and has all governmental licenses, authorizations, consents and approvals necessary to
execute and deliver this Agreement and to consummate the transactions contemplated by this Agreement.

 

(ii)
No Conflicts. None of the execution, delivery and performance of this Agreement by Company, or the consummation or the transactions
contemplated hereby and thereby

 

(a)
constitutes or will constitute a violation of the organizational documents of Company

 

(b)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice or lapse of time or both,
would constitute such a default) under, any indenture, mortgage, deed of Company, loan agreement, lease or other agreement or
instrument to which Company is a party or by which Company or any of its properties may be bound,

 

(c)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court or Governmental
Authority directed to Company or any of its properties in a proceeding to which its property is or was a party.

 

		8.	The
                                         terms and conditions of this Agreement shall be governed by and construed in accordance
                                         with the laws of the State or California. Any action to enforce this Agreement shall
                                         be brought in the state courts located in San Diego County, State of California.

 
Signed
in agreement

 

	/s/ Harry Lander PhD	 	 
	Harry Lander, Chairman & CEO	 	 
	“Company”	 	 
	Dated: April 6, 2016	 	 
	 	 	 

 

Signed
in acceptance

 

	/s/ Harry Lander	 	 
	“Employee”	 	 
	Dated: April 6, 2016Exhibit
10.3

WHEREAS,
Regen Biopharma, Inc. (the “Company”) wishes to reward and compensate Todd Caven (“Employee) for Employee’s
efforts in addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to the
Company’s Investigational New Drug Application for HemaXellerate.

WHEREAS,
Employee’s efforts have resulted in securing the consent of the FDA allowing the Company to initiate a Phase I clinical
trial assessing HemaXellerate in patients with drug-refractory aplastic anemia

WHEREAS,
the Company benefits greatly for having been granted the consent of the FDA allowing the Company to initiate a Phase I clinical
trial assessing HemaXellerate in patients with drug-refractory aplastic anemia

THERFORE,
IT IS AGREED AS FOLLOWS:

		9.	As
                                         bonus consideration for Employee’s labors, The Company shall award to Employee
                                         10 million shares of the Company’s Series A Preferred Stock, par value $0.0001(“Compensation
                                         Shares”)

		10.	Employee
                                         acknowledges that Compensation Shares have not been registered under the Securities Act
                                         of 1933, as amended (the “Act”), or securities laws of any state and may
                                         not be offered, sold, assigned, pledged, transferred or otherwise disposed of in the
                                         absence of an effective registration statement under the Act and applicable state securities
                                         laws or pursuant to an available exemption from registration under the Act or such laws.

 

		11.	Company
                                         hereby represents and warrants to Employee as follows;

 

		(iii)	Corporate
                                         Existence of Company.

Company:

 

(a)
is a corporation duly formed, validly existing and in good standing under the laws of the State of Nevada and

 

(b)
has all requisite power and authority, and has all governmental licenses, authorizations, consents and approvals necessary to
execute and deliver this Agreement and to consummate the transactions contemplated by this Agreement.

 

(ii)
No Conflicts. None of the execution, delivery and performance of this Agreement by Company, or the consummation or the transactions
contemplated hereby and thereby

 

(a)
constitutes or will constitute a violation of the organizational documents of Company,

  

(b)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice or lapse of time or both,
would constitute such a default) under, any indenture, mortgage, deed of Company, loan agreement, lease or other agreement or
instrument to which Company is a party or by which Company or any of its properties may be bound,

 

(c)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court or Governmental
Authority directed to Company or any of its properties in a proceeding to which its property is or was a party.

 

		12.	The
                                         terms and conditions of this Agreement shall be governed by and construed in accordance
                                         with the laws of the State or California. Any action to enforce this Agreement shall
                                         be brought in the state courts located in San Diego County, State of California.

 

Signed
in agreement

 

	/s/ Todd Caven	 	 
	Todd Caven, Chairman & CEO	 	 
	“Company”	 	 
	Dated: April 6, 2016	 	 
	 	 	 

 

Signed
in acceptance

 

	/s/ Todd Caven	 	 
	“Employee”	 	 
	Dated: April 6, 2016

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]